Drug Discovery, NAMs & Biomedical AI | DENVIS & ADMETrix Platforms | Greek SME DeepLab | Technical Partner

About

ORGANIZATION: DeepLab (Greek SME) – Deep-Tech AI/ML for Drug Discovery & Biomedical Research

WHO WE ARE:

DeepLab is a Greek SME specializing in advanced machine learning for drug discovery and biomedical research. We combine production-ready platforms with custom-tailored solutions—all designed with built-in interpretability for regulatory acceptance. 15+ years research, 8+ years industrial ML at scale, EU project experience (multilab.eu WP leadership).

PRODUCTION PLATFORMS:

- DENVIS – Ultra-fast virtual screening (1B+ molecules, 0.314ms/compound, JEDI Grand Challenge top-20/138)

- ADMETrix – De novo generation with real-time ADMET optimization (27 properties, DILI risk 93%→7%, first REINVENT + ADMET AI integration)

CORE CAPABILITIES:

- In silico NAMs: Computational alternatives to animal testing for early drug development

- Multi-omics integration: Genomics, transcriptomics, proteomics, metabolomics fusion

- Biomarker discovery & patient stratification algorithms

- Interpretable ML with uncertainty quantification for regulatory-grade evidence

- Graph Neural Networks for biological network analysis

PUBLISHED RESEARCH:

Deep-ID (interpretable precision medicine), pCCI (cell-cell interactions, IEEE BIBM 2023), Mask-cscGAN (synthetic data, IEEE Big Data 2023). All methodologies are indicative and are to be advanced and adapted to partner-specific data and requirements.